4061 - Treatment patterns for Resected Gastric Cancer Using the National Cancer Database.

Document Type


Publication Date



Background: The optimal management of patients with resected gastric cancer remains a therapeutic challenge. Although the benefit of peri-operative chemotherapy or adjuvant concurrent chemoradiotherapy for these patients is clearly established, recurrence and mortality rates remain high despite aggressive treatment. The goal of this study was to characterize the treatment patterns employed for patients with resected gastric cancer using the National Cancer Database (NCDB).

Methods: The NCDB was queried between 2004-2013 for patients with invasive resected gastric cancer and negative margins, excluding those with metastatic disease. Results: We identified a total of 21,156 cases. The median age was 67 (range 55-79). A majority of patients were white (74%) followed by black (14%) and other (12%). Most patients had either insurance through the government (58%) or private insurance (37%). 47% of patients had surgery alone with approximately 53% of these patients diagnosed with stage I gastric cancer. The remainder of the patients had radiation alone (1.4%), chemotherapy alone (15.2%), or combined chemotherapy and radiation (36.7%). Table 1 includes the further breakdown of treatment. Conclusions:A majority of patients with resected gastric cancer had treatment with either radiation, chemotherapy, or a combination of both. However, it is interesting to note that in patients receiving adjuvant or neoadjuvant treatment, only a portion of the patients received treatment options with level 1 evidence such as the MAGIC or McDonald regimens.


American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 3, 2017.